PRIBOMALProject ID: 37494
Pre-clinical studies towards an affordable, safe and efficacious two-component paediatric malaria vaccine
Total cost:EUR 3 585 326
EU contribution:EUR 2 345 358
Call for proposal:FP6-2005-LIFESCIHEALTH-7See other projects for this call
Funding scheme:STREP - Specific Targeted Research Project
Malaria is one of the major public health challenges in the world, causing more than one million deaths each year. The disease affects primarily children of the developing world, and it is understood to be both a disease of poverty and a cause of poverty. The available measures, such as personal protection or drugs, have proven insufficient to control the disease. A safe, affordable and efficacious paediatric malaria vaccine, which fits in the existing WHO Expanded Program on Immunization, would solve tremendous suffering to human kind.
Taking up this challenge, the PRIBOMAL consortium proposes to generate and test in pre-clinical models the safety and efficacy of an innovative malaria vaccine. The vaccine consists of a prime, to be administered at birth, of a proprietary novel recombinant BCG vector carrying three antigens derived from the Plasmodium falciparum parasite, the cause of malaria. The priming vaccine is followed at week 14 after birth by a booster vaccination using proprietary, industrially developed, recombinant adenoviral vector carrying the identical Plasmodium falciparum antigens as the rBCG-based malaria vaccine. The antigens inserted into the vaccine carriers are circumsporozoite protein, liver stage antigen-1 and sporozoite threonine and asparagine rich protein, which all three are proven highly immunogenic in humans.
Generation of these novel vaccine candidates as well as testing in established and novel pre-clinical models to determine potency and safety requires a combined European effort to bring together the required expertise on basic parasite biology, malaria epidemiology, disease onset and progression, recombinant vector technology, fundamental immunology, advanced animal models, and sophisticated proteomics. The international PRIBOMAL consortium proposed here bundles all required experience and as such deems itself well positioned to successfully conduct the research program proposed.
See on map
See on map